Literature DB >> 8822043

Increase in brain nitric oxide synthase activity in daunorubicin-treated rats.

P Joshi1, P J Vig, V Veerisetty, J A Cameron, B S Sekhon, D Desaiah.   

Abstract

Anthracyclines such as daunorubicin are very effective anticancer agents. These drugs are known to cause side effects including cardiotoxicity. Anthracyclines are neurotoxic to laboratory animals. Nitric oxide is a novel and very important chemical messenger in the brain. However, at higher levels, nitric oxide causes well defined neurotoxicity. Therefore, we determined nitric oxide synthase activity in rat brain after daunorubicin treatment in an effort to explain the neurotoxicity produced by anthracyclines. Male Sprague-Dawley rats were treated with different subcutaneous doses of daunorubicin (0.1-4.0 mg/kg/week for five weeks) while control animals were injected with phosphate buffered saline. There was a significant increase (80%) of nitric oxide synthase activity in daunorubicin-treated animals as compared to controls. This activity was inhibited by N-monomethyl-L-arginine (NMMA), nitroarginine, N-6-aminohexyl-5-chloro-1-napthalene sulfonamide (W-7), a calmodulin antagonist, suggesting that the nitric oxide synthase activity is calmodulin dependent. Further, our in vitro studies demonstrated that daunorubicin interacted with calmodulin as measured by N-phenyl-1-napthylamine (NPN) fluorescence. These results indicate that daunorubicin increases nitric oxide synthase activity in rat brain which may increase the levels of nitric oxide. The increased levels of nitric oxide may cause neurotoxicity. Our results further indicate that daunorubicin interacts with calmodulin and enhances nitric oxide synthase activity which is dependent on calmodulin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8822043     DOI: 10.1111/j.1600-0773.1996.tb00188.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  4 in total

1.  Characterization of three human cell line models for high-throughput neuronal cytotoxicity screening.

Authors:  Zhi-Bin Tong; Helena Hogberg; David Kuo; Srilatha Sakamuru; Menghang Xia; Lena Smirnova; Thomas Hartung; David Gerhold
Journal:  J Appl Toxicol       Date:  2016-05-03       Impact factor: 3.446

2.  Inadvertent intrathecal administration of daunomycin resulting in fatality: Case report and therapeutic considerations.

Authors:  Sauson Soldozy; Anant Patel; Kurt Yaeger; Daniel Felbaum; Steven M Spitz; Hasan R Syed; M Nathan Nair
Journal:  eNeurologicalSci       Date:  2020-11-28

3.  Differential roles of nitric oxide synthase isozymes in cardiotoxicity and mortality following chronic doxorubicin treatment in mice.

Authors:  Shiwei Deng; Anke Kruger; Albrecht Schmidt; Annegret Metzger; Tiandong Yan; Ute Gödtel-Armbrust; Gerd Hasenfuss; Friedrich Brunner; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-03-24       Impact factor: 3.000

4.  Assessing the Effects of Redox Modifier MnTnBuOE-2-PyP 5+ on Cognition and Hippocampal Physiology Following Doxorubicin, Cyclophosphamide, and Paclitaxel Treatment.

Authors:  Taylor McElroy; Taurean Brown; Fred Kiffer; Jing Wang; Stephanie D Byrum; Rebecca E Oberley-Deegan; Antiño R Allen
Journal:  Int J Mol Sci       Date:  2020-03-09       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.